SHL Medical

Startseite
Schweiz
Zug
SHL Medical

SHL Medical is a pioneering leader in advanced self-injection solutions such as autoinjectors and pen injectors.

SHL Medical is a pioneering leader in self-injection solutions, such as autoinjectors. Headquartered in Switzerland with sites across three continents, we offer end-to-end services, from design and development to final assembly, labeling, and packaging, partnering with pharma companies to deliver self-injection systems that enable patients’ independence. View SHL Medical trademarks: https://www.shl-medical.com/trademarks

21/04/2026

Day one at unfolded with thoughtful conversations.

Today’s discussions at Booth -42 showed a strong focus on self-injection device development, manufacturability, and long-term supply considerations in Japan and APAC markets.

Interests in Quanta and Reunite also led to deeper conversations around multi-dose strategies and reconstitution challenges for increasingly complex formulations, indicating continued innovation in response to changing therapy and program demands.

We look forward to building on these conversations over the coming days.

20/04/2026

Across the industry, pharma teams are placing greater emphasis on delivery platforms that can support both clinical flexibility and commercial-scale production.

SHL Medical will be part of these conversations in Boston during PFS and IDD East Coast 2026. Here's what you can expect at the event:
🔹 Explore our device portfolio, including Quanta, our multi-fixed-dose pen injector.
🔹 Learn more about our regional manufacturing capabilities supporting the US market.
🔹 Attend our session on multi-dose peptide delivery and production considerations.

Visit us at the Sheraton Boston Hotel from April 27–29.

17/04/2026

For people living with hemophilia A or B, treatment extends beyond controlling bleeds when they happen. Long-term care depends on maintaining consistent prophylactic treatment to help reduce the risk of bleeding episodes and joint damage over time.

As the treatment landscape evolves, newer therapies designed for subcutaneous administration offer an alternative to traditional intravenous infusions. Among these is the first FDA-approved hemophilia treatment delivered via a pre-filled, ready-to-use autoinjector, supported by SHL Medical’s device technology.

On , we recognize the importance of continued progress in care and the role of combination product innovation in making treatment for hemophilia A and B more practical and patient-centered.

At SHL Medical, we partner with pharma and biotech companies on device solutions that support reliable delivery and reduce complexity in self-administration.

16/04/2026

Platform approaches are already well established in drug delivery, valued for the efficiency and consistency they can bring. Their value often extends well beyond launch, for example as platforms are adapted across products. At the same time, many organizations also seek to leverage a single platform across multiple products or biosimilars.

At PDA Miniverse 2026, SHL Medical’s Dr. Nina Fetz will join Katy Rommel, PhD, of Kymanox for a joint presentation examining how companies can preserve the advantages of a stable device platform while still enabling technological innovation and scalable portfolio expansion.

The session will address practical strategies for evaluating and managing resulting challenges, including regulatory implications. We look forward to contributing to the discussion and connecting with peers at PDA Miniverse.

15/04/2026

In this interview with Drug Delivery Leader’s Chief Editor Tom Von Gunden, SHL Medical’s Courtney Nicholas Sutton shares perspectives on how advances in peptide-based treatments and evolving patient needs are shaping delivery innovation.

The conversation looks at:
🔹How treatment approaches and patient populations in cardiometabolic care are changing
🔹What is driving the shift toward new delivery approaches, including multi-dose systems
🔹The key challenges still to be addressed to support broader adoption, including patient safety, cost, and sustainability
🔹What the future patient experience could look like as delivery technologies continue to evolve

Watch the interview at Drug Delivery Leader website 👇

https://bit.ly/3ODMmVG

14/04/2026

When doses are measured at the microliter scale, visual alignment and user technique can introduce dose variability.

A comparative evaluation of a conventional syringe-and-needle system and a prefilled syringe incorporating SHL Medical’s Micro Dosing Device (MDD) technology demonstrated differences in dose variability between the two methods.

By mechanically controlling the delivered volume, the MDD approach reduced variability and improved alignment with the intended dose.

See how dose variability can be reduced 👉 https://bit.ly/3PHDRJi

13/04/2026

Next week in Tokyo, SHL Medical will be sharing how our device solutions are designed to support evolving program needs.

Alongside recently introduced solutions such as Quanta and Reunite, our team will also be discussing Molly and Maggie as part of our broader self-injection device portfolio, supporting different application and program considerations.

Our team will be available at Booth -42 to discuss how these devices, together with SHL Medical’s expertise and capabilities, support combination product programs across development and manufacturing stages.

We look forward to meeting you at .

10/04/2026

Most production delays are not caught at launch. They are locked in much earlier, through tooling decisions that shape how a device scales.

Cavity count is one of those decisions, and conventional approaches often require intermediate steps that add time, cost, and risk. SHL Medical’s pilot tool approach changes that by replicating high-cavitation conditions from the start, enabling scale-up in a single step. What once took 6-7 months of molding process development now takes 65 workdays.

Read the blog to see how it works, from scientific injection molding and design of experiments to the tooling and manufacturing setup behind it. 👇

https://bit.ly/3OevaWs

09/04/2026

At PFS and IDD East Coast 2026, Bart Burgess, Senior Vice President of Innovation and Product Strategy at SHL Medical, will discuss how emerging cardiometabolic therapies are influencing requirements for self-injection device development and production.

The session will use Quanta, our multi-fixed-dose pen injector, as a practical example to look at manufacturing, scalability, and operational considerations when preparing multi-dose peptide programs for larger patient populations.

If you’ll be in Boston, we welcome you to join the discussion.

08/04/2026

Early alignment between primary container and device platform can help prevent integration challenges and redesign work later in development.

In this short clip, Dr. Nina Fetz discusses why cartridge compatibility, device mechanics, and regulatory strategy need to be considered together in large-volume autoinjector development.

We’ll explore this topic further at the upcoming Pharmaversity® event in Boston on May 5, co-hosted by SHL Medical and SCHOTT Pharma.

Seats are limited. Learn more and register 👉 https://bit.ly/4lyCjx5

07/04/2026

Our week in South Korea highlighted how quickly the industry is developing in the APAC market, driving innovations in device design and development processes.

Across discussions, there was high interest in device strategies that balance dosing confidence, usability, and cost-effectiveness, alongside approaches that simplify the delivery of complex formulations.

Thank you to everyone who stopped by to share insights and perspectives. We look forward to continuing the conversation.

Next stop: Tokyo. See you at .

06/04/2026

Treating retinopathy of prematurity (ROP) often involves intravitreal injections at the microliter scale.

ROP affects premature infants and can lead to abnormal retinal blood vessel development. The condition progresses through defined stages (Stages 1–5), from mild retinal changes to total retinal detachment. In severe cases, this may result in vision loss.

For infants requiring treatment, doses are typically administered at around 10 µL per eye. Technologies such as SHL Medical’s Micro Dosing Device (MDD) support applications that require reliable low-volume dosing.

👉 Explore microliter-scale dosing in ROP: https://bit.ly/3PHDRJi

Adresse

Gubelstrasse 22
Zug
6300

Webseite

http://www.shl-medical.com/, https://www.shl-medical.com/trademarks

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von SHL Medical erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Die Praxis Kontaktieren

Nachricht an SHL Medical senden:

Verknüpfungen

Wollen Sie Ihr Praxis zum Top-Klinik in Zug machen?

Our Story

SHL Medical is a world-leading provider of drug delivery solutions. We design, develop, and manufacture advanced drug delivery devices such as autoinjectors, pen injectors, and wearable drug delivery systems. We also offer design-to-build and contract manufacturing services for products such as laboratory handling equipment, neurosurgical devices, and industrial equipment.

By integrating our experienced development teams with efficient manufacturing and a skilled workforce, we have developed a successful business model that allows us to provide comprehensive solutions for demanding requirements of the industry. As the largest company in SHL Group, SHL Medical continues to offer experience, excellence, and vision to customers and partners all over the world.